BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38602501)

  • 1. Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma.
    Gu H; Wang J; Ran W; Li G; Hu S; Zhao H; Wang X; Wang J
    J Pathol Clin Res; 2024 Mar; 10(2):e356. PubMed ID: 38602501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
    Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
    Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
    Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
    Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma.
    Xu B; Ghossein R
    Endocr Pathol; 2016 Sep; 27(3):205-12. PubMed ID: 27372303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
    Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
    J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.
    Toda S; Iwasaki H; Okubo Y; Hayashi H; Kadoya M; Takahashi H; Yokose T; Hiroshima Y; Masudo K
    Endocr J; 2024 Jan; 71(1):31-37. PubMed ID: 38044137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
    Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.
    Boruah M; Gaddam P; Agarwal S; Mir RA; Gupta R; Sharma MC; S Deo SV; Nilima N
    J Cancer Res Ther; 2023; 19(2):312-320. PubMed ID: 37006068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
    Adam P; Kircher S; Sbiera I; Koehler VF; Berg E; Knösel T; Sandner B; Fenske WK; Bläker H; Smaxwil C; Zielke A; Sipos B; Allelein S; Schott M; Dierks C; Spitzweg C; Fassnacht M; Kroiss M
    Front Endocrinol (Lausanne); 2021; 12():712107. PubMed ID: 34475850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DICER1 Mutations Do Not Always Indicate Dismal Prognosis in Pediatric Poorly Differentiated Thyroid Carcinomas.
    Yegen G; Altay AY; Yılmaz İ; İşcan Y; Sormaz İC; Aksakal N; Önder S; Mete Ö
    Endocr Pathol; 2023 Sep; 34(3):279-286. PubMed ID: 37574466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of
    Murugan AK; Qasem E; Al-Hindi H; Alzahrani AS
    Mol Clin Oncol; 2021 Oct; 15(4):210. PubMed ID: 34462665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.
    Pita JM; Figueiredo IF; Moura MM; Leite V; Cavaco BM
    J Clin Endocrinol Metab; 2014 Mar; 99(3):E497-507. PubMed ID: 24423316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
    Landa I; Ganly I; Chan TA; Mitsutake N; Matsuse M; Ibrahimpasic T; Ghossein RA; Fagin JA
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1562-6. PubMed ID: 23833040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy.
    Iñiguez-Ariza NM; Jasim S; Ryder MM; Chintakuntlawar AV; Morris JC; Hilger CR; Menefee ME; Smallridge RC; Karlin NJ; Alcaino C; Bible KC
    J Clin Endocrinol Metab; 2020 Jul; 105(7):e2346-57. PubMed ID: 32421817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
    Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
    Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
    [No Abstract]   [Full Text] [Related]  

  • 17. A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.
    Romei C; Elisei R
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
    Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
    [No Abstract]   [Full Text] [Related]  

  • 19. Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma.
    Nakazawa T; Nagasaka T; Yoshida K; Hasegawa A; Guo F; Wu D; Hiroshima K; Katoh R
    BMC Endocr Disord; 2022 Aug; 22(1):204. PubMed ID: 35971106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.
    Nikiforov YE
    Endocr Pathol; 2004; 15(4):319-27. PubMed ID: 15681856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.